mnk2 inhibitors (Biovitrum)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namemnk2 inhibitors (Biovitrum)
Drug Alias Namekinase modulator (Biovitrum)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMAP kinase-interacting serine/threonine-protein kinase 2 inhibitors
TargetsMAP kinase-interacting serine/threonine-protein kinase 2
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySweden
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSwedish Orphan Biovitrum Ab (Publ)
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSwedish Orphan Biovitrum Ab (Publ)
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A
Related LinksN/A